MaxCyte (LON:MXCT) Stock Price Crosses Below 50 Day Moving Average of $344.50

MaxCyte, Inc. (LON:MXCT) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 344.50 ($4.29) and traded as low as GBX 311.13 ($3.87). MaxCyte shares last traded at GBX 313 ($3.90), with a volume of 111 shares traded.

MaxCyte Price Performance

The stock has a 50 day simple moving average of GBX 343 and a two-hundred day simple moving average of GBX 337.74. The company has a market cap of £329.05 million, a price-to-earnings ratio of -1,079.31 and a beta of 1.04. The company has a debt-to-equity ratio of 8.07, a current ratio of 10.65 and a quick ratio of 14.38.

Insiders Place Their Bets

In other MaxCyte news, insider John Johnston sold 5,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of GBX 441 ($5.49), for a total transaction of £22,050 ($27,449.27). 1.30% of the stock is currently owned by corporate insiders.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.